Treatment, Medication & Supplement Directory
A comprehensive encyclopedia of medicines, chemotherapy protocols, targeted and immune therapies, supplements, Chinese herbal formulas, Traditional Chinese Veterinary Medicine (TCVM) approaches, and supportive-care options used or discussed in canine and feline tumor care. Directory entries explain what each option is, where it may fit, its evidence and safety boundaries, and what to discuss with a veterinarian; they are references, not individualized prescriptions or rankings.
Named profile Baituxiao Botanical Formula: Product, Label and Evidence ProfileRepresentative category illustration – no product packaging is shown.Baituxiao Botanical Formula: Product, Label and Evidence Profile
Baituxiao is marketed as a botanical supplement for pet wellness, comfort, vitality and normal immune function. It is not an FDA-approved cancer drug, and the manufacturer's own disclaimer…
Read more
Circulating Tumor DNA and Multi-Cancer Blood Tests: Evidence Boundary
Emerging blood-based cancer assays may be discussed for selected questions, but validation, false results, follow-up pathways, and device oversight require careful review.
Read more
Gemcitabine in Veterinary Oncology: Limited and Protocol-Specific Evidence
Gemcitabine is an intravenous antimetabolite considered in selected veterinary protocols, where evidence and toxicity must be reviewed for the exact diagnosis.
Read moreTaxane Chemotherapy: Formulation, Infusion, and Evidence Questions
Taxanes disrupt microtubule dynamics, but formulation, infusion reactions, species experience, and veterinary evidence differ enough that product names are not interchangeable.
Read more
Imatinib in Canine Mast Cell Tumor Care: Extra-Label Evidence Review
Imatinib has published canine mast cell tumor experience but is not interchangeable with veterinary-labeled TKIs and requires specialist, legal, formulation, and evidence review.
Read more
Medicinal Mushroom Extracts: Product-Specific Oncology Evidence
Mushroom products differ by species, extracted fraction, standardization, contaminants, and evidence; the word mushroom does not identify a tested intervention.
Read more
Turmeric and Curcumin: Bioavailability, Interaction, and Evidence Limits
Turmeric and curcumin products vary in extract, concentration, absorption enhancers, and purity, while robust canine cancer outcome evidence is lacking.
Read moreCBD and Cannabis Products in Pets With Cancer: Regulatory and Safety Boundary
FDA has not approved CBD for animal use, and product quality, THC contamination, interactions, liver effects, sedation, legal status, and cancer claims require caution.
Read moreChinese Herbal Formulas: Identification, Quality, and Evidence Review
A named traditional formula can vary by translation, ingredient, species, processing, manufacturer, and practitioner modification, so exact identification comes before benefit or safety claims.
Read moreYunnan Baiyao-Type Hemostasis Discussion: Preclinical Evidence Is Not Bleeding Control
Yunnan Baiyao is used anecdotally in veterinary bleeding plans, but formulation opacity and limited clinical evidence do not support relying on it to prevent or stop tumor hemorrhage.
Read more
Veterinary Cancer Clinical Trials: Eligibility, Consent, and Alternatives
A clinical trial may offer structured access to an investigational strategy or answer an important research question, but listing, enrollment, or novelty does not mean the study is…
Read moreNamed profile Jing Tang Stasis Breaker: Veterinary Product ProfileRepresentative category illustration – no product packaging is shown.Jing Tang Stasis Breaker: Veterinary Product Profile
Jing Tang Stasis Breaker is a named herbal formula for Dogs and cats; the current manufacturer page also lists horses; manufacturer positioning must be kept separate from independent…
Read more